The global erythropoietin market is expected to grow at a CAGR of 7.8% in the first half of the forecast period and CAGR of 4.8% in the second half of the forecast period. The market is estimated at $7.9bn in 2016 and $16.5bn in 2027.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 164-page report you will receive 84 tables and 93 figures – all unavailable elsewhere.
The 164-page report provides clear detailed insight into the global erythropoietin market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand new report today you stay better informed and ready to act.
Global Erythropoietin Market forecasts from 2017-2027
Revenue forecasts of global erythropoietin market, segmented by product type:
- Epoetin Alfa
- Epoetin Beta
- Darbepoetin Alfa
This section also discusses the leading drugs as well as SWOT analysis of each submarket.
Revenue forecasts of global erythropoietin market, segmented by application:
- Anemia (Cancer and HIV Treatment)
- Kidney Disorders (ESRD and Dialysis)
Revenue forecasts of global erythropoietin API manufacturing market, segmented by contract manufacturing and in-house manufacturing
Erythropoietin Leading Regional Market forecasts from 2017-2027 covering North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Forecast for each regional market is further segmented by product type, application and country:
- Rest of Europe
- Rest of Asia-Pacific
- Rest of Latin America
- Saudi Arabia
- South Africa
- Rest of Middle East and Africa
Assessment of selected leading companies that hold major market shares in the erythropoietin market:
- Johnson & Johnson
- Kyowa Hakko Kirin Co Ltd
- LG Life Sciences Limited
- Intas Pharmaceuticals Ltd
- Novartis AG
This study is intended for anyone requiring commercial analyses for the erythropoietin market. You find data, trends and predictions.